Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140

Benzinga · 19h ago
Leerink Partners analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $154 to $140.